TY - JOUR
T1 - Longitudinal study of falls among HIV-infected and uninfected women
T2 - The role of cognition
AU - Sharma, Anjali
AU - Hoover, Donald R.
AU - Shi, Qiuhu
AU - Holman, Susan
AU - Plankey, Michael W.
AU - Tien, Phyllis C.
AU - Weber, Kathleen M.
AU - Floris-Moore, Michelle
AU - Bolivar, Hector H.
AU - Vance, David E.
AU - Golub, Elizabeth T.
AU - McDonnell Holstad, Marcia
AU - Yin, Michael T.
N1 - Publisher Copyright:
© 2018 International Medical Press.
PY - 2018
Y1 - 2018
N2 - Background: Although fracture rates are higher in HIV+ HIV- women, including ≥2 falls in 25% HIV+ and 24% HIV-than HIV- women, whether HIV infection increases risk (overall P=0.30). Cognitive complaints were associated of falls is unclear. We determined the longitudinal occur-with falls among HIV+ (odds ratio [OR] 2.38; 95% CI 1.83, rence and risk factors for falls in the Women’s Intera-3.09) and HIV- women (OR 3.43; 95% CI 2.37, 4.97); in gency HIV Study (WIHS), and explored associations with adjusted models, cognitive complaints remained significant cognitive complaints. only in HIV- women (adjusted [aOR] 2.26; 95% CI 1.46, Methods: Recent (prior 6 months) self-reported falls were 3.48). Factors associated with any fall in adjusted analyses collected in 1,816 (1,250 HIV+; 566 HIV-) women over included: depressive symptoms and neuropathy (both HIV+ 24 months. Generalized estimating equation models using and HIV-); age, marijuana use, multiple CNS medications, stepwise selection determined odds of any fall (versus and HCV infection (HIV+ only); and cognitive complaints, none). quality of life, hypertension and obesity (HIV- only). Results: HIV+ women were older than HIV- women Conclusions: Middle-aged HIV+ and HIV- women had (median 49 versus 47 years; P=0.0004), more likely to similar fall rates. Among HIV+ women, factors affecting report neuropathy (20% versus 16%; P=0.023), and had cognition such as age, depressive symptoms, marijuana greater central nervous system (CNS) medication use. use and multiple CNS medications were important predic-At least one fall was reported in 41% HIV+ versus 42% tors of falls, however, cognitive complaints were not.
AB - Background: Although fracture rates are higher in HIV+ HIV- women, including ≥2 falls in 25% HIV+ and 24% HIV-than HIV- women, whether HIV infection increases risk (overall P=0.30). Cognitive complaints were associated of falls is unclear. We determined the longitudinal occur-with falls among HIV+ (odds ratio [OR] 2.38; 95% CI 1.83, rence and risk factors for falls in the Women’s Intera-3.09) and HIV- women (OR 3.43; 95% CI 2.37, 4.97); in gency HIV Study (WIHS), and explored associations with adjusted models, cognitive complaints remained significant cognitive complaints. only in HIV- women (adjusted [aOR] 2.26; 95% CI 1.46, Methods: Recent (prior 6 months) self-reported falls were 3.48). Factors associated with any fall in adjusted analyses collected in 1,816 (1,250 HIV+; 566 HIV-) women over included: depressive symptoms and neuropathy (both HIV+ 24 months. Generalized estimating equation models using and HIV-); age, marijuana use, multiple CNS medications, stepwise selection determined odds of any fall (versus and HCV infection (HIV+ only); and cognitive complaints, none). quality of life, hypertension and obesity (HIV- only). Results: HIV+ women were older than HIV- women Conclusions: Middle-aged HIV+ and HIV- women had (median 49 versus 47 years; P=0.0004), more likely to similar fall rates. Among HIV+ women, factors affecting report neuropathy (20% versus 16%; P=0.023), and had cognition such as age, depressive symptoms, marijuana greater central nervous system (CNS) medication use. use and multiple CNS medications were important predic-At least one fall was reported in 41% HIV+ versus 42% tors of falls, however, cognitive complaints were not.
UR - http://www.scopus.com/inward/record.url?scp=85047180363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047180363&partnerID=8YFLogxK
U2 - 10.3851/IMP3195
DO - 10.3851/IMP3195
M3 - Article
C2 - 28933703
AN - SCOPUS:85047180363
SN - 1359-6535
VL - 23
SP - 179
EP - 190
JO - Antiviral Therapy
JF - Antiviral Therapy
IS - 2
ER -